SunTrust analyst Peter Lawson cut his price target on Array after the company withdrew its application for FDA approval of its NRAS mutant melanoma drug, binimetinib, following a meeting with the FDA. The analyst says that the company believes that the data on the drug was not sufficient to support approval as a treatment for NRAS mutant melanoma. He lowered the chances of binimetinib's success as a treatment for mutated BRAF genes to 50% from 75% and consequently lowered his price target on the stock to $12 from $15.However, the analyst still believes that the company has at least two other potential positive catalysts and he keeps a Buy rating on the shares.

Northland downgraded Nextracker (NXT) to Market Perform from Outperform with a price target of $44, down from $60, ahead of the company's Q4 report on the view that Nextracker will be "hit with the same headwinds" Array Technologies (ARRY) and Shoals Technologies (SHLS) were hit by last quarter. The firm cites several reasons for the delayed impact on Nextracker, including a more aggressive effort to get product shipped to sites in a "good enough" position to take delivery and the fact that the company has not had to put out full-year guidance yet because of it's March 31 fiscal year end.

Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).